GlaxoSmithKline has revealed a series of new initiatives that are aimed at improving the company's delivery of new and better medicines to the diseased in the world's poorest countries.



The company is to encourage new research into neglected tropical diseases as well as expanding people in third world countries' access to medicines.



Andrew Witty, chief executive of GlaxoSmithKline, told the Council on Foreign Relations in New York: "We are working with world-class partners to find new business models to expand access to medicines and deliver unique solutions in all the communities where we work."



He went on to say that the company is "restless" and never satisfied with what it has achieved, always seeking to achieve more and delivering better health care.



The announcements were welcomed by one of GlaxoSmithKline's partners, Medicines for Malaria Venture, which has, over the last seven years, helped the pharmaceutical company to develop new, innovative medicines for malaria.



According to the NHS, malaria is preset in over 100 countries and comes in four different forms